Comment
doi: 10.1016/S2213-2600(23)00130-3.
Epub 2023 Mar 29.
Pirfenidone in rheumatoid arthritis-associated interstitial lung disease
Affiliations
- PMID: 37003283
- DOI: 10.1016/S2213-2600(23)00130-3
Item in Clipboard
Comment
Pirfenidone in rheumatoid arthritis-associated interstitial lung disease
Lancet Respir Med.
2023 Jun.
No abstract available
Conflict of interest statement
CTN has received a research grant and fees for lectures and advisory board meetings by Boehringer Ingelheim. NG and JL declare no competing interests.
Comment in
-
Pirfenidone in rheumatoid arthritis-associated interstitial lung disease - Authors' reply.Lancet Respir Med. 2023 Jun;11(6):e52. doi: 10.1016/S2213-2600(23)00131-5. Epub 2023 Mar 29. Lancet Respir Med. 2023. PMID: 37003284 No abstract available.
Comment on
-
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.Lancet Respir Med. 2023 Jan;11(1):87-96. doi: 10.1016/S2213-2600(22)00260-0. Epub 2022 Sep 5. Lancet Respir Med. 2023. PMID: 36075242 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
